Welcome to our dedicated page for Cardinal Health news (Ticker: CAH), a resource for investors and traders seeking the latest updates and insights on Cardinal Health stock.
Cardinal Health (NYSE: CAH), a leader in pharmaceutical distribution and healthcare supply chain solutions, maintains this dedicated news hub for investors and industry stakeholders. Our continuously updated repository provides official press releases, regulatory filings, and market-moving developments.
This resource delivers critical updates across CAH's core operations including pharmaceutical network expansions, medical-surgical product innovations, and strategic healthcare partnerships. Users gain access to essential documents such as quarterly earnings reports, SEC filings, and leadership announcements.
Key coverage areas include operational milestones in specialty drug distribution, advancements in clinical supply chain technology, and regulatory updates affecting global healthcare logistics. The curated format enables efficient tracking of CAH's market position within the competitive medical distribution sector.
Bookmark this page for direct access to primary-source Cardinal Health communications, ensuring informed decision-making through verified company disclosures. Combine regular monitoring with SEC.gov filings for comprehensive investment research.
Cardinal Health (NYSE: CAH) reported Q1 FY22 revenues of $44.0 billion, a 13% increase year-over-year. GAAP operating earnings were $415 million, contrasting with a $624 million loss in the prior year. However, non-GAAP operating earnings decreased 15% to $527 million. The Medical segment saw a 46% decline in profit due to rising supply chain costs. The company reaffirmed its full-year non-GAAP EPS guidance of $5.60 to $5.90, despite updated expectations for a decline in Medical segment profit.
Cardinal Health (NYSE: CAH) has announced a quarterly dividend of $0.4908 per share, set to be paid on January 15, 2022. Shareholders must be on record by the close of business on January 3, 2022 to receive this payment. This decision reflects the company’s commitment to returning value to its shareholders.
Cardinal Health emphasizes the significance of biosimilars in enhancing healthcare access during the second annual Global Biosimilars Week. Biosimilars, which are FDA-approved treatments that mirror biologics, play a vital role in reducing U.S. drug costs, projected to save $133 billion by 2025. Currently, there are 31 FDA-approved biosimilars in the U.S., with 20 available in the market, primarily targeting cancer and autoimmune diseases. Their anticipated entry into diabetes and ophthalmology markets promises lower treatment costs for millions of patients. Cardinal Health's leadership in the biosimilars sector aims to foster competition and innovation.
Suzanne Foster, president of
Cardinal Health (NYSE: CAH) has secured a $750,000 contract from the FDA for an 18-month study examining real-world evidence (RWE) in lymphoma treatment. The study, titled 'Assessment of a Novel Methodology for Endpoints Assessing Response to Lymphoma Treatment in Real-World Studies,' aims to compare real-world data (RWD) with central review standards in clinical trials. This initiative supports the FDA's increasing focus on RWE following the 21st Century Cures Act and seeks to improve patient outcomes through enhanced regulatory decision-making.
Cardinal Health (NYSE: CAH) announced a new range of cancer screening options in collaboration with FUJIFILM Healthcare and Polymedco. These options aim to address the significant decline in cancer screenings caused by the pandemic, which saw nearly 10 million screenings missed in the U.S. alone. The company now offers at-home testing for colon cancer, reducing barriers to early detection. Additionally, it provides solutions for liver cancer surveillance, critical for at-risk patients. Cardinal Health emphasizes the importance of accessible diagnostics to improve healthcare outcomes.
Journey Biosciences announced a collaboration with Cardinal Health's OptiFreight® Logistics to enhance kidney disease diagnostics for diabetes patients. This partnership aims to deliver the innovative NaviDKD diagnostic screening technology to healthcare providers, facilitating proactive management of Diabetic Kidney Disease (DKD). The deal focuses on improving logistics management, which is critical for timely diagnostics. Journey Biosciences seeks to transform diabetes care from reactive to proactive, emphasizing early detection and risk reduction.
Cardinal Health (NYSE: CAH) has expanded its Strategic Stock Solution, now serving nearly 40 hospitals and health systems nationwide, just a year after launch. This solution addresses challenges in pandemic preparedness by allowing health systems to order and store critical supplies, ensuring deliveries within 72 hours. Key features include inventory management using real-time analytics and significant logistical support. With a focus on enhancing supply chain resiliency, Cardinal Health aims to prepare medical facilities for future health emergencies, including the upcoming flu and RSV season.
AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have settled opioid-related claims with the Cherokee Nation for approximately $75 million over 6.5 years. This agreement resolves ongoing litigation and allows the companies to focus on safe medication delivery. The settlement is part of broader negotiations with federally recognized Native American tribes, despite the companies disputing the allegations against them. The firms emphasize their commitment to addressing the opioid epidemic's impact on communities.
FAQ
What is the current stock price of Cardinal Health (CAH)?
What is the market cap of Cardinal Health (CAH)?
